Humacyte, Inc. (HUMA)
HUMA moved a median of -0.33% 30 minutes after news, and -1.11% by the close. How HUMA actually reacts to news — the realized, point-in-time move the market made, measured across 1,019 labeled events over the last three years with zero look-ahead.
HUMA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.15% | 40% | 1,016 |
| 30-min | -0.33% | 43% | 1,016 |
| 60-min | -0.55% | 40% | 1,016 |
| to close | -1.11% | 40% | 1,013 |
| Middle 50% of HUMA reactions | -2.12% to +0.92% |
|---|---|
| Median reaction (30-min) | -0.33% |
| Measured reactions | 1,019 |
Half of all Humacyte, Inc. news events land between -2.12% and +0.92% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How HUMA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Rating reiterations | 144 | +0.10% | 52% | -1.14% |
| Price-target cuts | 13 | -0.17% | 46% | -1.36% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how HUMA ranks against every other measured name →
That’s how HUMA usually reacts — get an email when it moves on news →Email me when HUMA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to HUMA's baseline. Nothing else.
Recent HUMA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals | Press release | GlobeNewswire | -2.39% | +21.98% | |
| Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026 | Press release | GlobeNewswire | -0.23% | -2.60% | |
| Form 8-K Humacyte, Inc. For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | -2.66% | -3.04% | |
| Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik | Press release | GlobeNewswire | -1.64% | -0.51% | |
| Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | -3.45% | -2.22% | |
| Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months | Press release | GlobeNewswire | -0.05% | -1.95% | |
| Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions | Press release | GlobeNewswire | -1.13% | -1.90% | |
| Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results | Press release | GlobeNewswire | +8.25% | +22.48% | |
| Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement” | Press release | GlobeNewswire | +0.46% | +5.76% | |
| Form 10-Q Humacyte, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.59% | -14.20% | |
| Form 8-K Humacyte, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +1.15% | +2.31% | |
| Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +1.15% | +2.31% | |
| Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026 | Press release | GlobeNewswire | +2.41% | +0.76% | |
| Form 8-K Humacyte, Inc. For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | -0.26% | +4.44% | |
| Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting | Press release | GlobeNewswire | -1.01% | +5.25% | |
| Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access | Press release | GlobeNewswire | -0.63% | +4.00% | |
| Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting | Press release | GlobeNewswire | -0.46% | -0.93% | |
| Form 8-K Humacyte, Inc. For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -0.46% | -4.09% | |
| Form 8-K Humacyte, Inc. For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -2.64% | +2.86% | |
| Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients | Press release | GlobeNewswire | -2.64% | +2.86% | |
| Humacyte, Inc. Announces Pricing of Public Offering of Common Stock | Press release | GlobeNewswire | -2.64% | +2.86% | |
| Humacyte, Inc. Announces Proposed Public Offering of Common Stock | Press release | GlobeNewswire | -2.64% | +2.86% | |
| Form 8-K Humacyte, Inc. For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | -0.01% | -4.29% | |
| Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? | Press release | PR Newswire | +0.00% | +0.37% | |
| Form 8-K Humacyte, Inc. For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | -1.07% | -1.43% | |
| Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access | Press release | GlobeNewswire | -0.95% | +5.71% | |
| Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs | Press release | GlobeNewswire | +2.23% | +9.04% | |
| Form S-8 Humacyte, Inc. | SEC filing · Form S-8 | SEC EDGAR | -7.61% | -11.42% | |
| Form 10-Q Humacyte, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -6.96% | -13.04% | |
| Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +15.11% | +26.29% | |
| Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer | Press release | GlobeNewswire | -1.54% | -6.67% | |
| Form 8-K Humacyte, Inc. For: May 04 | SEC filing · Form 8-K | SEC EDGAR | -3.33% | -4.76% | |
| Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026 | Press release | GlobeNewswire | +0.94% | -0.94% | |
| Form DEF 14A Humacyte, Inc. For: Apr 28 | SEC filing · Form DEF | SEC EDGAR | -0.13% | +0.00% | |
| Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026 | Press release | GlobeNewswire | +1.34% | +13.51% | |
| Form 8-K Humacyte, Inc. For: Apr 21 | SEC filing · Form 8-K | SEC EDGAR | -0.15% | -1.17% | |
| Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess® | Press release | GlobeNewswire | -0.15% | -1.17% | |
| Humacyte Appoints Jim Mercadante as Chief Commercial Officer | Press release | GlobeNewswire | -1.41% | +3.66% | |
| Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair | Press release | GlobeNewswire | +0.37% | -3.82% | |
| Form PRE 14A Humacyte, Inc. For: Apr 17 | SEC filing · Form PRE | SEC EDGAR | -1.26% | -1.79% | |
| Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? | Press release | PR Newswire | -0.55% | -2.59% | |
| Form 10-K Humacyte, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -5.71% | -16.80% | |
| Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.60% | -9.92% | |
| Humacyte Appoints Rick McElheny as Senior Vice President of Business Development | Press release | GlobeNewswire | +0.57% | -6.22% | |
| Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026 | Press release | GlobeNewswire | -5.54% | +2.13% | |
| Form 8-K Humacyte, Inc. For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | -8.67% | -12.85% | |
| Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia | Press release | GlobeNewswire | -8.67% | -12.85% | |
| Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock | Press release | GlobeNewswire | -8.67% | -12.85% | |
| Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair | Press release | GlobeNewswire | +2.68% | +3.57% | |
| Humacyte To Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.88% | +2.75% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the HUMA section they belong to.
Where else HUMA is measured.
HUMA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Humacyte, Inc.'s median reaction calculated?
Every labeled HUMA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,019 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of HUMA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does HUMA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.